Lapatinib Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 250 mg, 500 mg
Reference Brands: Tykerb® (EU & US)
Category:
Oncology Cancer Care
Lapatinib is a targeted therapy for HER2-positive breast cancer, available in 250 mg and 500 mg oral tablets. Marketed as Tykerb® by GlaxoSmithKline, it inhibits the HER2 receptor to prevent cancer cell growth. Available in the US and EU, Lapatinib is sourced by B2B pharmaceutical wholesalers, ensuring reliable supply and GMP-compliant distribution for oncology clinics at competitive prices.
Lapatinib Tablet is available in Tablet
and strengths such as 250 mg, 500 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lapatinib Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lapatinib Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lapatinib is a targeted cancer therapy used in the treatment of HER2-positive breast cancer. As a tyrosine kinase inhibitor (TKI), it inhibits the HER2 receptor, a key driver of cancer cell growth. Available in 250 mg and 500 mg oral tablets, Lapatinib is marketed under the brand name Tykerb® by GlaxoSmithKline and is also available in generic forms. Widely sourced by B2B pharmaceutical wholesalers in the US and EU, Lapatinib ensures reliable supply for oncology clinics and cancer centers. Its GMP-compliant distribution offers competitive pricing, making it a key player in breast cancer treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing